EODData

MEMBERSHIP REGISTER LOG IN

OTCBB, RSPI: Respirerx Pharmaceuticals Inc

13 Nov 2025
LAST:

0.0018

CHANGE:
 0.00		OPEN:
0.0018		HIGH:
0.0018		ASK:
0.0000		VOLUME:
11.3K
CHG(%):
0.00		PREV:
0.0018		LOW:
0.0018		BID:
0.0000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
13 Nov 250.00180.00180.00180.001811.3K
11 Nov 250.00180.00180.00180.0018100
10 Nov 250.00180.00180.00180.0018200
07 Nov 250.00180.00180.00180.0018300
06 Nov 250.00140.00140.00140.0014200
05 Nov 250.00150.00150.00150.0015600
04 Nov 250.00140.00140.00140.001490.0K
31 Oct 250.00110.00110.00110.0011183.1K
30 Oct 250.00150.00150.00110.00111.9K
29 Oct 250.00180.00180.00180.0018300

PROFILE

Name:Respirerx Pharmaceuticals Inc
About:RespireRx Pharmaceuticals Inc. engages in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. It has two drug platforms comprising ResolutionRx, a pharmaceutical cannabinoids platform, which includes dronabinol that acts upon the CB1 and CB2 endocannabinoid receptors for use in chemotherapy-induced nausea and vomiting, as well as for anorexia in patients with AIDS and obstructive sleep apnea; and EndeavourRx, a neuromodulators platform that comprises AMPAkines program, including proprietary compounds that are positive allosteric modulators (PAMs) of glutamate receptors to promote neuronal function, and GABAkines program, including proprietary compounds that are PAMs of GABAA receptors. The company's lead ampakine, CX1739, which has completed Phase II clinical studies for opioid-induced respiratory depression, as well as for central sleep apnea. It is also developing CX717, CX1739, and CX1942 that have clinical application in the treatment of CNS-driven neurobehavioral and cognitive disorders, spinal cord injury, neurological diseases, and various orphan indications. It has a research collaboration with University College London to the use of AMPAkines for the treatment of GRIA disorders. The company was formerly known as Cortex Pharmaceuticals, Inc. and changed its name to RespireRx Pharmaceuticals Inc. in December 2015. RespireRx Pharmaceuticals Inc. was incorporated in 1987 and is headquartered in Glen Rock, New Jersey.
Sector:Healthcare
Industry:Biotechnology
Address:126 Valley Road, Glen Rock, NJ, United States, 07452
Website:https://www.respirerx.com
CUSIP:761227305
CIK:0000849636
ISIN:US7612273059
FIGI:BBG000GRPPL6

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

TECHNICAL INDICATORS

MA5:0.005.9%
MA10:0.0012.5%
MA20:0.0020.0%
MA50:0.0038.5%
MA100:0.0038.5%
MA200:0.0028.6%
STO9:100.00 
STO14:100.00 
RSI14:50.00
MTM14:0.00
ROC14:0.20 
ATR:0.00 
Week High:0.000.0%
Week Low:0.0028.6%
Month High:0.000.0%
Month Low:0.0028.6%
Volatility:425.58 

RECENT SPLITS

Date Ratio
06 Jan 20211-10